Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2025 07:55 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

Inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complications.